| Hans-Günter Meyer-Thompson | Fachveröffentlichungen
Encephalopathy following subcutaneous administration of Brixadi® extended-release buprenorphine.
Encephalopathy following subcutaneous administration of Brixadi® extended-release buprenorphine.
Seltzer J, Moriguchi R, Yeung K, Shindo Y, Hardin J, Galust H, Minns A, Clark R.
Toxicol Rep. 2026 Jul 22;17:102320. doi: 10.1016/j.toxrep.2026.102320. PMID: 42571226; PMCID: PMC13451788.